Skip to content
Screener

R&D at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$258M-13.1%
Haemonetics logo
HaemoneticsHAE
$16.2M-0.4%
Utah Medical Products logo
Utah Medical ProductsUTMD
$154K+14.1%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$22.61M+0.6%
ICU Medical logo
ICU MedicalICUI
$22.7M+3.8%
UFP Technologies logo
UFP TechnologiesUFPT
$2.15M-17.3%

Segments

By segment

See full
EMEA$26.33M+236%
Americas$12.98M+13.1%
Asia$3.51M-29.3%

Other financials

Income statement

See full
Revenue$570.3M+28.9%
Gross profit$331.7M+24.8%
Operating income$72.8M-20.1%
Net income$99.7M-18.7%
EPS (diluted)$2.28-17.7%

Balance sheet

See full
Cash & equivalents$316.9M+23.5%
Total debt$3.0B+49.5%
Total equity$2.9B-31.5%
Total assets$6.8B-8.0%

Cash flow

See full
Operating cash flow$91.9M+348%
CapEx$14.0M-49.5%
Free cash flow$77.9M+220%

Valuation

See full
Market cap$6.15B+24.1%
Enterprise value$8.81B+31.7%
P/S2.7×-0.1×

Profitability

See full
Gross margin46.7%-4.5pp
Operating margin2%-14.9pp
Net margin-45.8%-56.9pp
FCF margin7.9%

Returns & leverage

See full
Return on equity-28.9%-33.2pp
Debt / equity+0.6×
Current ratio2.6×+0.2×

Where this comes from

Reported directly by Teleflex in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Teleflex’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 3:08 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000096943-26-000095
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 29, 2025Six Months Ended / June 30, 2026Six Months Ended / June 29, 2025
Cost of goods sold238,625176,695479,461335,522
Gross profit331,707265,830639,133521,261
Selling, general and administrative expenses213,515137,504439,527290,419
Research and development expenses45,12226,48889,50851,783
Restructuring charges, separation costs and impairment charges24610,70017,09112,122
Income from continuing operations before interest, taxes and loss on extinguishment of debt72,82491,13893,007166,937
Interest expense27,95321,70353,67140,240
Interest income(1,416)(1,229)(3,124)(2,717)

Item 1. Financial Statements (Unaudited):

FAQ

What is Teleflex's R&D?
Teleflex (TFX) reported R&D of $45.12M in Q2 2026.
How has Teleflex's R&D changed year-over-year?
Teleflex's R&D increased by 70.3% year-over-year, from $26.49M to $45.12M.
What is the long-term trend for Teleflex's R&D?
Over 4 years (2021 to 2025), Teleflex's R&D has grown at a -1.8% compound annual growth rate (CAGR), from $130.84M to $121.64M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Ask your AI about Teleflex's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude